MIRA Pharmaceuticals, Inc. (NasdaqCM: MIRA)
Health Care · Pharmaceuticals · US
$0.76
-2.13% today · -47.3% 1Y
MIRA Pharmaceuticals, Inc. (NasdaqCM: MIRA) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $32.79M and employs 2 people.
Over the last twelve months the share price has lost 47.3%, trading between 0.60 and 2.45.
Tweenvest scores MIRA Pharmaceuticals, Inc. across four factors: quality 26/100. Its strongest factor is quality.
MIRA price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $32.79M
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -0.86
- Dividend yield
- —
- Beta (5Y)
- 1.55
- 52-week high
- $2.45
- 52-week low
- $0.60
- Avg volume (3M)
- —
- Shares outstanding
- 42.02M
- Employees
- 2
- Next earnings
- —
About MIRA Pharmaceuticals, Inc.
MIRA Pharmaceuticals, Inc. operates as a biopharmaceutical enterprise currently in the clinical development phase. Its main objective involves the creation and market introduction of a novel synthetic tetrahydrocannabinol (THC) analog. This compound is undergoing investigation for its potential to address anxiety and the cognitive impairments frequently observed in adult patients suffering from early-stage dementia. The firm's lead candidate, MIRA1a, is a synthetic cannabinoid analog engineered to alleviate both anxiety and chronic pain through its interaction with cannabinoid type 1 and type 2 receptors. Originally established in 2020 as MIRA1a Therapeutics, Inc., MIRA Pharmaceuticals, Inc. maintains its headquarters in Baltimore, Maryland.
- Founded
- 2020
- Listed since
- Aug 3, 2023
- Exchange
- Nasdaq Capital Market
- Currency
- USD
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Eli Lilly and CompanyNYSE: LLY | $1.12T | $1,255.40 | +0.88% |
| Johnson & JohnsonNYSE: JNJ | $651.25B | $270.24 | +1.07% |
| Merck & Co., Inc.NYSE: MRK | $376.37B | $152.55 | +2.39% |
| Roche Holding AGSWX: ROP | $373.91B | CHF375.60 | +1.02% |
| Novartis AGSWX: NOVN | $302.17B | CHF127.42 | +0.85% |
| AstraZeneca PLCLSE: AZN | $258.76B | £122.40 | +1.26% |
| Novo Nordisk A/SCPSE: NOVO B | $207.84B | Dkr300.85 | +1.59% |
| Pfizer Inc.NYSE: PFE | $159.99B | $28.07 | +1.01% |
Figures last refreshed Aug 18, 2026.